MyFinsight
Home
Blog
About
Proceeds from draw down of
debt
$70,000K
(-63.16%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$41,968K
(46.25%↑ Y/Y)
Proceeds from issuance of
common stock upon...
$13,474K
(-74.23%↓ Y/Y)
Net cash provided by
financing activities
$48,146K
(-24.55%↓ Y/Y)
Canceled cashflow
$77,296K
Net decrease in cash
$14,744K
(219.51%↑ Y/Y)
Canceled cashflow
$33,402K
Repayment of debt
$70,000K
(-63.54%↓ Y/Y)
Payment of contingent
consideration
-$3,050K
(32.04%↑ Y/Y)
Payments of tax
withholdings on stock awards
$2,834K
(-45.75%↓ Y/Y)
Payments on principal
portion of finance lease...
$1,210K
(31.66%↑ Y/Y)
Cash paid for common
stock issuance costs
$202K
(-77.80%↓ Y/Y)
Accrued expenses and
other current...
$46,610K
(108.81%↑ Y/Y)
Stock-based compensation
expense
$27,148K
(-43.35%↓ Y/Y)
Prepaid expenses and
other current assets
-$2,146K
(-149.22%↓ Y/Y)
Amortization of intangible
asset
$1,589K
(-49.73%↓ Y/Y)
Right-of-use asset
amortization for finance...
$1,155K
(21.71%↑ Y/Y)
Non-cash lease expense
$857K
(-40.15%↓ Y/Y)
Non-current inventory and
other assets
-$855K
(-126.53%↓ Y/Y)
Amortization of debt discount
$164K
(-83.33%↓ Y/Y)
Depreciation
$143K
(-46.84%↓ Y/Y)
Net cash used in
operating activities
-$32,952K
(56.53%↑ Y/Y)
Net cash used in
investing activities
-$450K
(-28.21%↓ Y/Y)
Canceled cashflow
$80,667K
Net loss
-$51,314K
(52.22%↑ Y/Y)
Purchases of equipment
$450K
(28.21%↑ Y/Y)
Accounts payable
-$27,733K
(-241.27%↓ Y/Y)
Accounts receivable, net
$26,397K
(-53.55%↓ Y/Y)
Inventories, net
$5,890K
(190.72%↑ Y/Y)
Gain in fair value of
contingent consideration
-$1,496K
(77.30%↑ Y/Y)
Operating lease liability
-$789K
Revenue
$218,375K
Gain in fair value of
contingent consideration
-$1,496K
(77.30%↑ Y/Y)
Segment net loss
-$51,314K
(52.22%↑ Y/Y)
Canceled cashflow
$219,871K
Selling and marketing
expense (excluding...
$164,113K
Stock-based compensation
expense
$27,148K
(-43.35%↓ Y/Y)
General and
administrative expense...
$24,615K
Cost of revenue
(excluding amortization...
$13,564K
Research and development
expense...
$13,397K
Research and development
expense...
$11,491K
Research and development
expense...
$4,584K
Research and development
expense...
$3,544K
Other research and
development
$3,073K
Research and development
expense...
$2,399K
Other segment items
$1,717K
Interest expense, net
-$1,540K
Back
Back
Cash Flow
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)
source: myfinsight.com